Dr Kenichi Takayasu and colleagues from Japan elucidated factors affecting survival of the patients with unresectable hepatocellular carcinoma.
The patients also underwent transcatheter arterial lipiodol chemoembolization.
The team performed a nationwide prospective cohort study over the past 8 years.
The patients underwent transcatheter arterial lipiodol chemoembolization using emulsion of lipiodol and anticancer agents followed by gelatin sponge particles as an initial treatment.
Exclusion criteria were extrahepatic metastases and/or any previous treatment prior to the present transcatheter arterial lipiodol chemoembolization.
The researchers' primary end point was survival.
The survival rates were calculated by the Kaplan-Meier method.
The team used the Cox proportional hazard model for multivariate analyses of the factors affecting survival.
|Tumor-node-metastasis stage is an independent risk factors for patient survival
The mean follow-up period was 2 years.
The researchers found that the 1-, 3-, 5-, and 7-year survivals were 82%, 47%, 26%, and 16%, respectively.
Both the degree of liver damage and the tumor-node-metastasis system proposed by the Liver Cancer Study Group of Japan demonstrated good stratification of survivals.
The multivariate analyses showed significant difference in degree of liver damage, α-fetoprotein value, maximum tumor size, number of lesions, and portal vein invasion.
The team noted that the last 3 factors could be replaced by tumor-node-metastasis stage.
The transcatheter arterial lipiodol chemoembolization-related mortality rate after the initial therapy was less than 1%.
Dr Takayasu's team concluded, “Transcatheter arterial lipiodol chemoembolization showed safe therapeutic modality with a 5-year survival of 26% for unresectable hepatocellular carcinoma patients.”
“The degrees of liver damage, tumor-node-metastasis stage, and α-fetoprotein values were independent risk factors for patient survival.”